Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97773239

Filing Date: 01/30/2023

To the Commissioner for Trademarks:

MARK: AZEMBL (Standard Characters, see mark)
The literal element of the mark consists of AZEMBL. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Allergan Pharmaceuticals International Limited, a An Ireland Private Company Limited by Shares legally organized under the laws of Ireland, having an address of
      Clonshaugh Business & Technology Park
      Dublin 17 D17E400
      Ireland
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  pharmaceutical preparations to treat infections; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



The owner's/holder's proposed attorney information: Cheryl A. Withycombe. Other appointed attorneys are Janie Thompson, Matthew O. Brady. Cheryl A. Withycombe of AbbVie Inc., is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      Mail code: AND-250C
      18655 Teller Avenue
      Irvine, California 92612
      United States
      847-937-3386(phone)
      847-938-2623(fax)
      cheryl.withycombe@abbvie.com
The docket/reference number is AZEMBL.
Cheryl A. Withycombe submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Cheryl A. Withycombe

PRIMARY EMAIL FOR CORRESPONDENCE: cheryl.withycombe@abbvie.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): trademarks@abbvie.com; kimberly.gleason@abbvie.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Cheryl A. Withycombe/   Date: 01/30/2023
Signatory's Name: Cheryl A. Withycombe
Signatory's Position: Attorney of Record/CA Bar Member
Signatory's Phone Number: 847-937-3386
Signature method: Sent to third party for signature
Payment Sale Number: 97773239
Payment Accounting Date: 01/30/2023

Serial Number: 97773239
Internet Transmission Date: Mon Jan 30 15:40:49 ET 2023
TEAS Stamp: USPTO/BAS-XXX.XXX.XXX.XXX-20230130154049
747574-97773239-8604f3bddbc586b9730f2f02
82f87c37435cd9adfefb3f11e1ccd19c6f44e0d7
-DA-40490610-20230130131807216601